NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $1.30 -0.06 (-4.41%) Closing price 04:00 PM EasternExtended Trading$1.30 -0.01 (-0.38%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quince Therapeutics Stock (NASDAQ:QNCX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$1.30▼$1.4350-Day Range$0.84▼$1.4352-Week Range$0.51▼$2.45Volume375,488 shsAverage Volume299,802 shsMarket Capitalization$59.11 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewQuince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Read More… Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreQNCX MarketRank™: Quince Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 973rd out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingQuince Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQuince Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Quince Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuince Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quince Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.45% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 16.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.45% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 16.21%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.60 News SentimentQuince Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Quince Therapeutics this week, compared to 1 article on an average week.Search Interest11 people have searched for QNCX on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Quince Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address QNCX Stock News HeadlinesQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesJune 18 at 4:21 PM | businesswire.comQuince Therapeutics raises $11.5 million in private placementJune 14, 2025 | investing.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.June 20, 2025 | American Alternative (Ad)Quince Therapeutics Raises $11.5M in Private PlacementJune 13, 2025 | tipranks.comQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesJune 12, 2025 | businesswire.comQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJune 3, 2025 | businesswire.comQuince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026May 15, 2025 | seekingalpha.comQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finance.yahoo.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $1.87 on January 1st, 2025. Since then, QNCX shares have decreased by 30.5% and is now trading at $1.30. View the best growth stocks for 2025 here. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.10. Who are Quince Therapeutics' major shareholders? Top institutional shareholders of Quince Therapeutics include Ieq Capital LLC (1.83%), Intellectus Partners LLC (0.12%) and Virtu Financial LLC (0.10%). Insiders that own company stock include Dirk Thye, Brendan Hannah, Charles S Ryan and Ted Monohon. View institutional ownership trends. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include Athenex (ATNX), PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU). Company Calendar Last Earnings5/13/2025Today6/20/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QNCX CIK1662774 Webwww.quincetx.com Phone(650) 910-5717FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$11.00 Low Stock Price Target$4.00 Potential Upside/Downside+507.9%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-117.52% Return on Assets-34.22% Debt Debt-to-Equity Ratio0.82 Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book1.91Miscellaneous Outstanding Shares45,469,000Free Float36,239,000Market Cap$59.84 million OptionableOptionable Beta0.80 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:QNCX) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersWhat a “Mar-a-Lago Accord” could mean for the US dollar.25-Year Market Vet Issues Urgent Dollar Warning He's spent 25 years tracking the flow of global money - now...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.